[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610661":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":29,"centralContacts":34,"locations":40,"responsibleParty":56,"collaborators":11,"id":58,"slug":11,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":11,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":11,"enrollmentInfo":66,"targetDuration":11,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":11,"overallStatus":42,"whyStopped":11,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Keymed Biosciences Co.Ltd","INDUSTRY",[8,14,17,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1","EXPERIMENTAL",null,[13],"Biological: CM512",{"label":15,"type":10,"description":11,"interventionNames":16},"Group 2",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Group 3",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"Group 4",[13],[24],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"BIOLOGICAL","CM512","CM512 subcutaneous injection",[9,15,18,21],[30],{"name":31,"affiliation":32,"role":33},"Jianzhong Zhang","Peking University People's Hospital","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":11,"email":39},"Qian Jia","CONTACT","+86-028-88610620","qianjia@keymedbio.com",[41],{"facility":32,"status":42,"city":43,"state":44,"zip":11,"country":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Beijing","Beijing Municipality","China",{"type":47,"coordinates":48},"Point",[49,50],116.39723,39.9075,{"lat":50,"lon":49},[53],{"name":31,"role":37,"phone":54,"phoneExt":11,"email":55},"15545433012","rmzjz@126.com",{"type":57,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100610661",false,"NCT07230483","A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.","An Open-Label, Multicenter Study to Evaluate Long-Term Safety and Efficacy of CM512 in Atopic Dermatitis Patients.","Inclusion Criteria:\n\n* Have the ability to understand the study and voluntarily sign a written informed consent form (ICF).\n* Subjects who have completed the week 18 evaluation in the parent study CM512-101102 or the End of Study(EOS) visit in the parent study CM512-100001.\n\nExclusion Criteria:\n\n* Not enough washing-out period for previous therapy.\n* Any other condition assessed by the investigator that makes participants unsuitable for participation in this study.","ALL","18 Years",{"count":67,"type":68},246,"ESTIMATED","INTERVENTIONAL",[71],"PHASE2","This is an Open-label ,Multicenter Study to evaluate Long-Term Safety and Efficacy of CM512 in patients with Atopic Dermatitis who have completed treatment in parent CM512 Study.",[74],"Atopic Dermatitis (AD)","2025-11-13",{"date":77,"type":78},"2025-11-17","ACTUAL",{"date":80,"type":68},"2025-12",{"date":82,"type":68},"2027-12",{"name":5,"class":6},1]